InflaRx N.V. (IFRX)
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
Address
WINZERLAER STR. 2
JENA, 2M 07745
Founded
2007
Number of Employees
66
Website
http://www.inflarx.de
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at IFRX make a trade.
Creating a free account takes less than one minute